Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$2.14 USD
-0.08 (-3.39%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.15 +0.01 (0.47%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 121 - 140 ( 199 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Responses and Correlation With H-Score In Line With Expectations.
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From KOL Dinner: XMT-1536 Has the Makings of a Compelling ADC
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updating SGO Expectations Post FY19 Corporate Update; Target to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SGO a Go for Additional ''1536 Data, More to Come Later in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expectations for XMT-1536 at the SGO on March 30, 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expected Data Flow, and Available Activity and Safety Profile Bode Well for XMT-1536; Raising Target to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Onward and Upward; Escalation/Expansion Panning Favorably, Clarification on Activity Could Revitalize This ADC Pureplay
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D